How many email patterns does AgeneBio use?

AgeneBio uses 2 known email patterns.

What domain does AgeneBio use for work emails?

AgeneBio uses agenebio.com for work email addresses.

Most Common Email Formats at AgeneBio

AgeneBio's most common email format is First.Last@agenebio.com (ex. John.Doe@agenebio.com), used for 75% of agenebio.com addresses. AgeneBio uses 2 email patterns.

@agenebio.com

2 patterns

Format	Example	Share of agenebio.com
First.Last@agenebio.comMost common	John.Doe@agenebio.com	75%
First@agenebio.com	John@agenebio.com	25%

Frequently Asked Questions

What does AgeneBio do?

AgeneBio operates in the Pharmaceutical Manufacturing industry, alongside similar companies like Roche, Cerevel Therapeutics and Alector. You can visit agenebio.com or contact AgeneBio's headquarters by phone at

+1-443-451-****

. Explore AgeneBio's company overview page for more information.

What is AgeneBio's email address format?

AgeneBio's email format typically follows the pattern of First.Last@agenebio.com; this email format is used 75% of the time. Other contacts within LeadIQ's database had email formats such as First@agenebio.com. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does AgeneBio have currently?

AgeneBio has approximately 3 employees as of October 2026. Key team members to contact include Director Of Cm&c: K. P., Senior Manager: M. S. and Real Estate: L. B. For more team information and contact data, explore AgeneBio's employee directory with LeadIQ.

AgeneBio Email Format

Q: What is AgeneBio's email address format?

AgeneBio's email format typically follows the pattern of ${fn}.${ln}. Other email formats include ${fn}.

Pharmaceutical ManufacturingMaryland, United States2-10 Employees

AgeneBio is a small pharmaceutical company based in Baltimore, Maryland, focused on developing therapies to prevent neurodegeneration and maintain or restore cognitive function for unserved patients with amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, as well as other neurological and psychiatric disorders. Its work is grounded in decades of research, including studies from Johns Hopkins University, that point to hippocampal overactivity as a driver of cognitive impairment and neurodegeneration. AGB101 is the company’s lead candidate and is described as Phase 3-ready, aimed at addressing hippocampal overactivity. In addition, AgeneBio is pursuing a novel GABA-A alpha5 small molecule program in late discovery stage with potential applications across conditions such as aMCI, autism, and schizophrenia. Overall, AgeneBio operates within the pharmaceutical manufacturing sector, concentrating on therapies for neurological and psychiatric diseases.

Most Common Email Formats at AgeneBio

@agenebio.com

Need a specific person's email?

Frequently Asked Questions

What does AgeneBio do?

What is AgeneBio's email address format?

How many employees does AgeneBio have currently?

AgeneBio Email Format

Ready to create more pipeline?

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Most Common Email Formats at AgeneBio

@agenebio.com

Need a specific person's email?

Frequently Asked Questions

What does AgeneBio do?

What is AgeneBio's email address format?

How many employees does AgeneBio have currently?

AgeneBio Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.